A CXCR4 receptor agonist strongly stimulates axonal regeneration after damage

Giulia Zanetti1, Samuele Negro1, Aram Megighian1,2, Andrea Mattarei3, Florigio Lista4, Silvia Fillo4, Michela Rigoni1, Marco Pirazzini1 & Cesare Montecucco1,5

1Department of Biomedical Sciences, University of Padua, Padua, Italy
2Padua Neuroscience Center, University of Padua, Padua, Italy
3Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy
4Scientific Department, Army Medical Center, Roma, Italy
5CNR Institute of Neuroscience, Padua, Italy

Correspondence
Marco Pirazzini and Cesare Montecucco, Department of Biomedical Sciences, University of Padua, Padua, Italy. Tel: +39 049 827 6058; Fax: +39 049 827 6049; E-mail: marcopiraz@gmail.com and cesare.montecucco@gmail.com

Funding information
This study was supported by the Italian Ministry of Defence (Progetto RIPCANE to CM), by the University of Padua (Progetto BIRD 2018 to MP and DOR to MR), and by Fondazione CARITRO (Cassa di Risparmio di Trento e Rovereto) with a postdoctoral fellowship (Bando per giovani ricercatori coinvolti in Progetti di Eccellenza to G.Z).

Received: 30 July 2019; Revised: 30 September 2019; Accepted: 2 October 2019

Annals of Clinical and Translational Neurology 2019; 6(12): 2395–2402
doi: 10.1002/acn3.50926

Giulia Zanetti and Samuele Negro authors are contributed equally.

Abstract

Objective: To test whether the signaling axis CXCL12α-CXCR4 is activated upon crush/cut of the sciatic nerve and to test the activity of NUCC-390, a new CXCR4 agonist, in promoting nerve recovery from damage. Methods: The sciatic nerve was either crushed or cut. Expression and localization of CXCL12α and CXCR4 were evaluated by imaging with specific antibodies. Their functional involvement in nerve regeneration was determined by antibody-neutralization of CXCL12α, and by the CXCR4 specific antagonist AMD3100, using as quantitative read-out the compound muscle action potential (CMAP). NUCC-390 activity on nerve regeneration was determined by imaging and CMAP recordings. Results: CXCR4 is expressed at the injury site within the axonal compartment, whilst its ligand CXCL12α is expressed in Schwann cells. The CXCL12α-CXCR4 axis is involved in the recovery of neurotransmission of the injured nerve. More importantly, the small molecule NUCC-390 is a strong promoter of the functional and anatomical recovery of the nerve, by acting very similarly to CXCL12α. This pharmacological action is due to the capability of NUCC-390 to foster elongation of motor neuron axons both in vitro and in vivo. Interpretation: Imaging and electrophysiological data provide novel and compelling evidence that the CXCL12α-CXCR4 axis is involved in sciatic nerve repair after crush/cut. This makes NUCC-390 a strong candidate molecule to stimulate nerve repair by promoting axonal elongation. We propose this molecule to be tested in other models of neuronal damage, to lay the basis for clinical trials on the efficacy of NUCC-390 in peripheral nerve repair in humans.

Introduction

The peripheral nervous system (PNS) is exposed to a variety of damages, from mechanical traumas to autoimmune or neurotoxic attacks. In humans, peripheral nerve injuries may also derive from surgical resections like those occurring during excision of tumors. For its essential roles in physiology and survival, the PNS has retained throughout evolution the capability to regenerate. Nevertheless, several factors, including injury type, its anatomical location, and the extent of associated inflammation, can limit the extent of the repair process. The mechanisms and players of peripheral nerve regeneration are intensively investigated, as the molecular and cellular understanding of the regeneration process will lead to the discovery of chemical and biological molecules to improve rehabilitation of PNS neurons after accidents. In addition, there is the possibility that the same actors may be beneficial for the central nervous system, where regeneration is poor.

Recently, we found that the chemokine CXCL12α potently promotes the recovery of the neuromuscular
junction (NMJ) activity after degeneration of the motor axon terminal.6 In this process, CXCL12α is synthesized and released by perisynaptic Schwann Cells (SC), and acts via the CXCR4 receptor re-expressed on the tip of the regenerating motor axon terminal.6

CXCL12α (also known as SDF-1) is a secreted chemokine discovered as a growth factor for the bone marrow pre-B cells,7,8 and later shown to be involved in the development of various regions of the central nervous system.9–11 As other chemokines, it acts via a G protein coupled receptor, dubbed CXCR4, forming a signaling axis involved in a variety of responses in the immune and nervous systems.12–18 Given its nature as modulator of the immune system, CXCL12α is susceptible to post-translational modifications and hydrolysis in body fluids that block/attenuate its biological activity, bioavailability and half-life, resulting in poor pharmacokinetics properties.19 In addition, CXCL12α structure consists of 93 amino acids, 5 cysteines, and 2 disulfide bridges which makes its production via recombinant methods complicated and very costly.

On the other hand, as CXCR4 is the co-receptor driving the entry of HIV into human immune cells, in addition to its involvement in a variety of regulatory and modulatory activities of the immune and nervous systems,15,20 an intensive search for CXCR4 antagonists and agonists with favorable pharmacokinetics is ongoing. A novel group of CXCR4 ligands was recently identified and, among them, a new molecule, dubbed NUCC-390, displayed the best capability to activate the receptor in a cell line.21

Here, we describe the finding that the expression of CXCL12α and CXCR4 increases at the site of sciatic nerve crush, and we report compelling evidence that the stimulation of CXCR4 with the agonist NUCC-390 accelerates neurotransmission rescue mainly by promoting axonal elongation.

Materials and Methods

Reagents

NUCC-390 synthesis was performed as previously described.22 AMD3100, a strong CXCR4 antagonist, was from Abcam (120718). Cytosine β-D-arabinofuranoside (C6645), DNase I (DN25), poly-L-lysine (P1274), laminin (L2020), and trypsin (T4799) were from Sigma Aldrich. µ-conotoxin GIIIB was from Alomone. Primary antibodies: β3-tubulin (302302, Synaptic System), NF (ab4680, Abcam), CXCR4 (ab1670, Abcam), GAP43 (ab75810, Abcam), CXCL12α (Cell Signaling, BK3740S). Secondary antibodies were from Thermo Scientific.

Animals and Ethical statement

C57BL/6 mice expressing cytosolic GFP under the plp promoter23 were kindly provided by Dr. W. Macklin (Aurora, Colorado) and Dr. T. Misgeld (Munchen, Germany). They were used in imaging experiments. CD1 mice were from the local animal facility, and were employed for electrophysiological recordings. Animal care and experimental procedures were performed in accordance with National laws and policies (D.L. n. 26, March 14, 2014), with the guidelines established by the European Community Council Directive (2010/63/EU), and were approved by the local authority veterinary services.

Sciatic nerve injury, electrophysiology, and immunostaining

Six-eight week-old CD1 or C57BL6-J plp-GFP mice were anesthetized with xylazine (48 mg/kg) and zoletil (16 mg/kg) via i.p. injection. The sciatic nerve was exposed and crushed or cut as described.24,25 Briefly, an incision was made in the skin that is gently dissected from the underlying musculature. Then the fascial plane between the gluteus maximus and the anterior head of the biceps femoris was open revealing the sciatic nerve. The nerve was then gently freed from the surrounding connective tissue, and cut using small surgical scissors or, alternatively, placed on the bottom jaw of a super-fine haemostatic forceps for the crush. The nerve was crushed once for 40 sec with three clicks of the haemostatic forceps predipped in powdered carbon, used to mark the crush site. Finally, the gluteal musculature was re-opposed and the skin sutured using 6-0 braided silk, nonabsorbable sutures (ETHL-1, 0–0, USA), fed to a PC using an A/D interface (BNC-2110, Naperville, IL, USA). Traces were recorded with WinEDR, and analyzed using pClamp10. CMAP values from one hind limb muscle were normalized to those from the contralateral one of the same mouse, which received the same treatment (i.e. injection of either the agonist, or the antagonist, or of the neutralizing antibodies), thus making the result independent of muscle fiber dimensions.

© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
For immunostaining, sciatic nerves from C57BL6-J plp-GFP mice were fixed in 4% paraformaldehyde for 10 min at RT, quenched in 50 mmol/L NH4Cl, and saturated in blocking solution containing 0.5% Triton X-100. Incubation with antibodies was performed for >48 h in blocking solution. After washings and incubation with secondary antibodies, images were collected with a SP5 confocal microscope (Leica, Germany). Where indicated, whole mount staining was performed as in.26

**Neuronal cultures and axon length quantification**

Cultures of spinal cord motor neurons (SCMNs) were prepared as previously described.27 After plating, neurons were exposed for 24 h to the indicated concentrations of either NUCC-390, or AMD3100, or their combination in culture medium. Cells were fixed for 10 min (4% paraformaldehyde), stained for β3-tubulin, and examined by epifluorescence microscopy (Leica DMIRE2). Axon length was quantified with NeuronJ (ImageJ).

**Statistical analysis**

A group size of seven mice allowed to detect a difference in the mean values between groups with a power of 80% and a statistical significance of 5% in in vivo experiments. At least three independent replicates for cell culture experiments were conducted in blind. Data are expressed as mean ± SEM. GraphPad Prism software was used for all statistical analyses. Statistical significance was calculated by ANOVA with Tukey post-test, or two-tailed unpaired Student's t-test depending on the number of groups analysed. Data were considered statistically different when *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

**Results**

**The CXCR4 receptor and its ligand CXCL12α are strongly expressed in the sciatic nerve after crush**

We tested the expression of CXCL12α and CXCR4 after axonal damage in a well-established model of traumatic neuronal injury consisting in the compression (crush) of the sciatic nerve.3,24 The crush causes interruption of many axons, mostly of myelinated ones, with preservation of Schwann cells (SC) and the basal lamina (BL), which are essential for nerve regeneration to take place. Figure 1 shows the expression of CXCR4 in longitudinal (A–B) and cross-sections (C) collected consecutively (slices of 20 μm thickness each) in control sciatic nerves or over the lesion site in after crush. CXCR4 is barely detectable in noninjured nerves, but its signal strongly increases in the axonal compartment after damage where it co-localizes with neurofilament (NF). Neurons negative for CXCR4 are likely to be those neurons whose axons were spared by the crush, or that were already beyond the regeneration front. Also CXCL12α expression increases in the crushed area 3 and 7 days after injury (D), but in this case the signal mainly colocalizes with GFP, suggesting expression mainly by SC. However, given the known biological activities of CXCL12α and the inflammatory reaction triggered by nerve compression, it is possible that inflammatory cells recruited in the damaged area, as well as resident cells such as endoneural, endothelial cells and fibroblasts, do express CXCL12α, thus explaining the staining pattern at 3 days post crush (Fig. 1 panel D). We did not pursue further this aspect as we mainly focused on the signaling axis formed by CXCL12α and CXCR4 expressed by SC and neurons, respectively, following axonal damage. The comparison of the crushed nerves at 3 and 7 days indicates that the increase in CXCL12α expression induced by the injury is transient, with the chemokine almost disappearing after 7 days. At variance, the expression of CXCR4 is more persistent, a finding that speaks in favor of a therapeutic use of a CXCR4 agonist.

**The CXCL12α-CXCR4 axis is involved in the functional recovery upon crush**

To assess the functional role of the CXCL12α-CXCR4 axis in the recovery from nerve injury we measured the compound muscle action potential (CMAP) in gastrocnemius muscles of crushed CD1 mice treated either with a specific antibody neutralizing CXCL12α, or with AMD3100, a specific CXCR4 antagonist, as schematically indicated in Figure 2A. Both treatments cause a strong delay in neuro-transmission recovery. This is quantified in panel B of Figure 2, which reports the CMAP areas of injured nerves (2 weeks after crush), showing that the inhibition of either components of the axis delays regeneration.

**The CXCR4 agonist NUCC-390 promotes neuromuscular recovery after sciatic nerve crush**

The finding that CXCL12α is expressed for a limited time period after nerve injury (Fig. 1D) suggests that it may function as initiator of the repair process. At the same time, as CXCR4 expression persists longer (Fig. 1C), even when its ligand is no more detectable, we reasoned that a prolonged stimulation of the receptor might foster regeneration. As CXCL12α displays a very poor pharmacokinetics
In vivo, we treated crushed mice with the chemical compound NUCC-390, which was recently shown to act similarly to CXCL12 in a cell culture system. CMAP areas measured in gastrocnemius muscles 7, 14, and 28 days after injury clearly indicate that NUCC-390 is a good promoter of the functional recovery of the sciatic nerve after crush (Fig. 2D–E). The accelerated recovery of neurotransmission by NUCC-390 is also indicated by the faster disappearance of the multiple peaks beside the main biphasic shape in the CMAP trace, indicative of a synchronous stimulation of the muscle fibers upon electrical stimulation of the entire nerve. Such a pharmacological effect arises from the specific interaction of NUCC-390 with CXCR4, as it is prevented by AMD3100, a selective

Figure 1. CXCR4 and CXCL12α are expressed at the crushed site of the sciatic nerve. (A) Longitudinal cryo-sections of control (top) and crushed (bottom) sciatic nerves show CXCR4 expression (red). Dotted lines define the crushed area (the proximal site of the injury is on the left). (B) Higher magnification of the crush site. Scale bars: 500 μm (A), 50 μm (B). (C) Cross-sections of sciatic nerves from mice expressing cytosolic GFP (green) specifically in SC, of controls (top panels), and after 3 (middle panels) or 7 days (bottom panels) from nerve crush. Neurofilament (NF) staining (blue) identifies the axonal compartment; CXCR4 is in red. CXCR4 co-localizes with NF, restricting its expression to the axonal compartment. Scale bars: 50 μm. Right panels show higher magnifications (scale bar: 10 μm). (D) Cross-sections of sciatic nerves show CXCL12α expression (red) at the crushed site 3 and 7 days after crush. Right panels show higher magnifications. Scale bars: 50 μm (right panels: 10 μm). Images are representative of at least three independent sets of experiments.
antagonist of the CXCR4 receptor (Fig. 2F). These results suggest that NUCC-390 holds a great potential as therapeutics for damaged peripheral nerves.

**NUCC-390 stimulates axonal elongation**

By using an *in vitro* system consisting of primary cultures of spinal cord motor neurons (SCMNs) we found that NUCC-390 stimulates axonal elongation and that this activity is mediated by CXCR4, being it blocked by AMD3100 (Fig. 3C,D).

NUCC-390 induces elongation of motor axons (Fig. 3A,B), and that this activity is mediated by CXCR4, being it blocked by AMD3100 (Fig. 3C,D).

The axonal elongation activity of NUCC-390 is displayed also *in vivo* after nerve transection (an injury that cuts both axons and BL, making regeneration incomplete) as indicated by the evident staining of GAP43, a biochemical marker of active axonal re-growth (Fig. 3E).28

Figure 2. CXCR4 engagement promotes the recovery of neuromuscular activity after sciatic nerve injury. (A) Scheme of the experimental workflow. After sciatic nerve crush mice were treated either with an antibody neutralizing CXCL12α, or with AMD3100, or with vehicle. CMAP was recorded at day 14. (B) Histogram reports the area of CMAP traces 14 days after sciatic nerve crush. (C) Scheme of NUCC-390 administration after sciatic nerve crush, and time-course of CMAP recordings. (D) Histogram reporting the area of CMAP traces at the indicated time points after sciatic nerve crush (± NUCC-390). (E) Representative CMAP traces at different time points after sciatic nerve crush (± NUCC-390). Black arrows indicate the stimulation artifact. For each trace, the scale of CMAP amplitude is reported on the right. (F) Histogram showing the area of CMAP traces 14 days after sciatic nerve crush in mice treated either with vehicle, or with NUCC-390 in combination with AMD3100. [Correction added on 06 December 2019 after first online publication: Figure 2 has been updated.]
NUCC-390 treatment increases the density of axons in active regrowth in the proximal side, and the number of axons entering the bridge area. On the contrary, AMD3100 prevents the pharmacological effect of NUCC-390, by reducing both the density and the number of GAP43-positive axons entering the bridge segment connecting the distal and the proximal stumps of the nerve. This result confirms that NUCC-390 action on axonal regeneration takes place via CXCR4.

Discussion

The major findings of the present work are the following: (i) an injury to the sciatic nerve triggers the expression of...
the signaling axis CXCL12α-CXCR4 at the damaged site; (ii) this axis is functionally involved in nerve regeneration because specific inhibition of both components delays the recovery of neuromuscular function; (iii) the CXCR4 agonist NUCC-390 promotes the functional rescue of peripheral nerves by stimulating motor nerve elongation. The latter activity, shared by CXCL12α (the natural CXCR4 ligand) and NUCC-390 (CXCR4 agonist), is suggested by the in vitro experiments with cultured motor neurons, by the in vivo effects on CMAP rescue, and by the imaging with specific markers. However, one cannot exclude that the in vivo effects of CXCL12α and NUCC-390 may also result from still unknown activities or signaling mediated by CXCR4 in the neuronal cell body within ganglia and in the ventral horn of the spinal cord.

The in vivo activity of NUCC-390 described here holds a great potential translational value. In fact, given the ongoing intense research for novel therapies for injured peripheral neurons,29,30 these results have relevant clinical implications, as they indicate NUCC-390 as a potential pro-regenerative drug to be tested in different animal models of PNS disorders. We recently found that NUCC-390 strongly promotes the functional recovery of motor nerve terminals after the acute degeneration induced by α-latrotoxin at the neuromuscular junction,22 a model that recapitulates several aspects of autoimmune neuropathies caused by auto-antibodies against peripheral axon antigens.31 In addition, NUCC-390 activity could be tested in neurodegenerative conditions, like amyotrophic lateral sclerosis, where fostering regenerative programs may help in slowing down disease progression. If positive results will arise from these studies, NUCC-390 would become a strong candidate therapeutics to be evaluated in human peripheral neurotraumas, neuropathies, and neuromuscular disorders.

**Author Contributions**

M.R., M.P., and C.M. conceived the project and supervised the study; G.Z., S.N., A.Ma, and A.M. performed the experiments; F.L. and S.F. contributed to data analysis; M.R., M.P., and C.M. wrote the manuscript, with contributions of all authors.

**Conflicts of Interest**

Nothing to report.

**References**

1. Sanes JR, Lichtman JW. Development of the vertebrate neuromuscular junction. Annu Rev Neurosci 1999;22:389–442.
2. Darabid H, Perez-Gonzalez AP, Robitaille R. Neuromuscular synaptogenesis: coordinating partners with multiple functions. Nat Rev Neurosci 2014;15:703–718.
3. Tintignac LA, Brenner HR, Ruegg MA. Mechanisms regulating neuromuscular junction development and function and causes of muscle wasting. Physiol Rev 2015;95:809–852.
4. Li L, Xiong WC, Mei L. Neuromuscular junction formation, aging, and disorders. Annu Rev Physiol 2018;10:159–188.
5. Rigoni M, Montecucco C. Animal models for studying motor axon terminal paralysis and recovery. J Neurochem 2017;142(Suppl 2):122–129.
6. Negro S, Lessi F, Duregotti E, et al. CXCL12alpha/SDF-1 from perisynaptic Schwann cells promotes regeneration of injured motor axon terminals. EMBO Mol Med 2017;9:1000–1010.
7. Tashiro K, Tada H, Heilker R, et al. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 1993;261:600–603.
8. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA 1994;91:2305–2309.
9. Bagri A, Gurney T, He X, et al. The chemokine SDF1 regulates migration of dentate granule cells. Development 2002;129:4249–4260.
10. Chalasani SH, Sabelko KA, Sunshine MJ, et al. A chemokine, SDF-1, reduces the effectiveness of multiple axonal repellents and is required for normal axon pathfinding. J Neurosci 2003;23:1360–1371.
11. Lieberam I, Agalliu D, Nagasawa T, et al. A Cxcl12-CXCR4 chemokine signaling pathway defines the initial trajectory of mammalian motor axons. Neuron 2005;47:667–679.
12. Wang J, Knaut H. Chemokine signaling in development and disease. Development 2014;141:4199–205.
13. Nagasawa T. CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med (Berl) 2014;92:433–439.
14. Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393:595–599.
15. Pozzobon T, Goldoni G, Viola A, Molon B. CXCR4 signaling in health and disease. Immunol Lett 2016;177:6–15.
16. Zhu Y, Matsumoto T, Mikami S, et al. SDF1/CXCR4 signalling regulates two distinct processes of precerebellar neuronal migration and its depletion leads to abnormal pontine nuclei formation. Development 2009;136:1919–1928.
17. Guyon A. CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front Cell Neurosci 2014;8:65.
18. Mithal DS, Banisadr G, Miller RJ. CXCL12 signaling in the development of the nervous system. J Neuroimmun Pharmaco 2012;7:820–834.
19. Villalba S, Salvucci O, Aoki Y, et al. Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo. J Leukoc Biol 2003;74:880–888.
20. Cammack N. Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target. Antivir Chem Chemother 1999;10:53–62.

21. Mishra RK, Shum AK, Platanias LC, et al. Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists. Sci Rep 2016;6:30155.

22. Negro S, Zanetti G, Mattarei A, et al. An agonist of the cxcr4 receptor strongly promotes regeneration of degenerated motor axon terminals. Cells. 2019;8: https://doi.org/10.3390/cells8101183.

23. Mallon BS, Shick HE, Kidd GJ, Macklin WB. Proteolipid promoter activity distinguishes two populations of NG2-positive cells throughout neonatal cortical development. J Neurosci 2002;22:876–885.

24. Bauder AR, Ferguson TA. Reproducible mouse sciatic nerve crush and subsequent assessment of regeneration by whole mount muscle analysis. J Vis Exp 2012: https://doi.org/10.3791/3606.

25. Park S, Liu CY, Ward PJ, Jaiswal PB, English AW. Effects of repeated 20-hz electrical stimulation on functional recovery following peripheral nerve injury. Neurorehabil Neural Repair 2019;33:775–784.

26. Dun XP, Parkinson DB. Visualizing peripheral nerve regeneration by whole mount staining. PLoS ONE 2015;10:e0119168.

27. Rigoni M, Pizzo P, Schiavo G, et al. Calcium influx and mitochondrial alterations at synapses exposed to snake neurotoxins or their phospholipid hydrolysis products. J Biol Chem 2007;282:11238–11245.

28. Benowitz LI, Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 1997;20:84–91.

29. Scheib J, Hoke A. Advances in peripheral nerve regeneration. Nat Rev Neurol 2013;9:668–676.

30. Doron-Mandel E, Fainzilber M, Terenzio M. Growth control mechanisms in neuronal regeneration. FEBS Lett 2015;589:1669–1677.

31. Rodella U, Scorzeto M, Duregotti E, et al. An animal model of Miller Fisher syndrome: Mitochondrial hydrogen peroxide is produced by the autoimmune attack of nerve terminals and activates Schwann cells. Neurobiol Dis 2016;96:95–104.